Inflammasomes are multi-protein signalling scaffolds that assemble in response to invasive pathogens and sterile danger signals to activate inflammatory caspases (1/4/5/11), which trigger inflammatory death (pyroptosis) and processing and release of pro-inflammatory cytokines 1,2 . Inflammasome activation contributes to many human diseases, including inflammatory bowel disease, gout, type II diabetes, cardiovascular disease, Alzheimer's disease, and sepsis, the often fatal response to systemic infection 3-6 .
marrow-derived macrophages (iBMDMs) before activating the canonical inflammasome with nigericin or the non-canonical inflammasome by LPS electroporation. Only C- 23 (disulfiram) blocked pyroptosis in cells, with IC 50 values of 7.67 ± 0.29 µM and 10.33 ± 0.50 µM for canonical and non-canonical inflammasome-dependent pyroptosis, respectively ( Fig. 1g-j) , and impaired cell death triggered by the AIM2 inflammasome in mouse iBMDMs transfected with poly(dA:dT) (Extended Data Fig. 1e ). Disulfiram also inhibited nigericin-or LPS transfection-induced IL-1β secretion with potency comparable to the pan-caspase inhibitor z-VAD-fmk ( Fig. 1k,l) .
Disulfiram is being investigated as an anticancer agent because epidemiological studies showed that individuals taking disulfiram for alcohol addiction were less likely to die of cancer 24 .
In cells disulfiram is rapidly metabolized to diethyldithiocarbamate (DTC) 25, 26 . The anti-cancer activity of DTC in vivo is greatly enhanced by complexation with copper 24 , likely because of the enhanced electrophilicity of the DTC thiols. In liposome leakage assay, we found that copper gluconate (Cu 2+ ) only weakly increased disulfiram or DTC inhibition ( Fig. 2a ); we interpret this as due to the high reactivity of the GSDMD Cys residue involved (see below). However, Cu 2+ strongly promoted the ability of either disulfiram or DTC to protect LPS-primed THP-1 cells from pyroptosis ( Fig. 2b) . With Cu 2+ , the IC 50 of disulfiram for inhibiting pyroptosis decreased 24-fold to 0.41 ± 0.02 µM, which was similar to its potency for preventing liposome leakage. DTC became almost as active as disulfiram in cells in the presence of Cu 2+ .
Because disulfiram inhibited pyroptosis and IL-1β release in cells, we next tested its ability to protect C57BL/6 mice from LPS-induced sepsis. Mice were treated with vehicle or disulfiram intraperitoneally before challenge with LPS. Whereas the lowest concentration of LPS (15 mg/kg) killed 3 of 8 control mice after 96 hrs, all the disulfiram-treated mice survived (P < 0.05) ( Fig. 2c ).
Serum IL-1β concentrations were strongly reduced 12 hrs after LPS challenge when all mice were alive (281 ± 149 ng/mL in disulfiram-pretreated mice, 910 ± 140 ng/mL in control mice (P < 0.0001)) ( Fig. 2d ). Following LPS challenge at the intermediate concentration (25 mg/kg), all the control mice died within 72 hrs, but 5 of 8 of the disulfiram-treated mice survived (P < 0.01) ( Fig.   2e ). At the highest LPS challenge (50 mg/kg), while all the control mice died within a day, death was significantly delayed by disulfiram treatment and 1 of 8 mice survived (P < 0.0001) ( Fig. 2f ).
To determine if we could delay treatment until after LPS challenge and whether adding copper could improve protection, we challenged mice with 25 mg/kg LPS intraperitoneally and administered disulfiram with or without copper gluconate immediately and 24 hrs later. Post-LPS treatment still improved survival (P = 0.041 without copper and P = 0.024 with copper). All the control mice and mice treated without copper died, but 2 of 8 mice given copper-complexed disulfiram survived (Fig. 2g ). Thus, disulfiram given before or after LPS partially protected mice from septic death and reduced IL-1β secretion.
Disulfiram has been shown to inactivate reactive Cys residues by covalent modification 27 . To probe the mechanism of GSDMD inhibition by disulfiram, we used nano-liquid chromatography-tandem mass spectrometry (nano-LC-MS/MS) to analyse disulfiram-treated human GSDMD. Tryptic fragments indicated a dithiodiethylcarbamoyl adduct of Cys191, in which half of the symmetrical disulfiram molecule is attached to the thiol (Fig. 3a, b, Extended Data Fig. 2) . Indeed, Cys191 is required for GSDMD pore formation in cells, since oligomerization was blocked by Ala mutation of the corresponding Cys192 in mouse GSDMD 8 .
This Cys residue, conserved in GSDMD, but not in other GSDM family members, is accessible in both the full-length autoinhibited structure model and the N-terminal pore form model, generated based on mouse GSDMA3 structures 7, 14 (Fig. 3c, Extended Data Fig. 3a ). Corresponding to Leu183 of GSDMA3, Cys191 sits at the distal tip of the membrane spanning region at the beginning of the β8 strand within the β7-β8 hairpin, which is a key element in the β-barrel that forms the pore 14 . Analysis of Cys reactivity using PROPKA 28 suggests that Cys191 is the most reactive among all Cys residues in GSDMD. Consistent with its high reactivity, a time course analysis showed that disulfiram inhibited liposome leakage within 2 min of incubation (Extended Data Fig. 3b ). To confirm that disulfiram acts on Cys191, we generated Ala mutations of Cys191, and of Cys38 as a control. Whereas the disulfiram IC 50 values for WT and C38A were both around 0.3 µM in the liposome leakage assay, the IC 50 for C191A was about 8-fold higher ( Fig.   3d ). We also incubated disulfiram with N-acetylcysteine (NAC), which contains a reactive Cys that can inactivate Cys-reactive drugs, before assessing whether disulfiram protects THP-1 cells from nigericin-mediated pyroptosis. As expected, NAC eliminated the activity of disulfiram ( Fig.   3e ). These data together suggest that disulfiram inhibits GSDMD pore formation by selectively and covalently modifying Cys191.
Disulfiram has been reported to inhibit caspases by binding to the catalytic Cys responsible for proteolysis 29 . It is therefore likely that disulfiram inhibits both caspases and GSDMD. Using a fluorogenic caspase activity assay that measures the release of 7-amino-4-methylcoumarin (AMC) from substrate Ac-YVAD-AMC, we found that disulfiram indeed inhibited caspase-1 and caspase-11 (Extended Data Fig. 4 ). To determine the relative contribution of caspase-11 inhibition versus GSDMD inhibition by disulfiram in pore formation, we replaced the caspase cleavage site in GSDMD with the rhinovirus 3C protease site (GSDMD-3C) and used the 3C protease instead of caspase-11 in the liposome leakage assay. The resulting IC 50 was 0.52 ± 0.03 µM, comparable to 0.30 ± 0.01 µM for caspase-11-triggered liposome leakage ( Fig. 1e, Fig.   3f ). By contrast, as mouse GSDMA3 lacks the conserved Cys191, disulfiram inhibited liposome leakage triggered by 3C-cleaved GSDMA3 containing a 3C protease site (GSDMA3-3C) with a much weaker IC 50 of 12.14 ± 2.10 µM ( Fig. 3g ). Thus, we conclude that the inhibitory effect of disulfiram in the liposome leakage assay is mainly mediated by direct inhibition of GSDMD.
To determine the structure-activity relationship (SAR) of disulfiram, we evaluated a set of disulfiram analogues and found that a number of small alkyl-substituted thiuram disulfides had IC 50 values in liposome leakage assay comparable to or marginally better than disulfiram (Extended Data Fig. 5a ,b). Potency was mildly negatively correlated with the steric bulkiness of the substituents, presumably due to the need for the core thiuram disulfide chemical motif to access the reactive Cys (Extended Data Fig. 5a,b ). Several small alkyl-substituted thiuram disulfides also significantly protected against nigericin-induced pyroptosis in THP-1 cells, albeit less potent than disulfiram (Extended Data Fig. 5c -e).
To identify additional inhibitors of pyroptosis, we expanded our liposome leakage screen to test 86,050 additional compounds in the ICCB-Longwood collection. 343 hit compounds inhibited liposome leakage by at least 50% ( Fig. 4a ). However, when these were tested in a high throughput cell viability assay for inhibition of the canonical inflammasome pathway in THP-1 cells, only 2 compounds inhibited cell death by ≥ 50%. One was the pan-caspase inhibitor z-VAD-fmk and the other was Bay 11-7082, a previously known inhibitor of NF-κB activation 13 and the NLRP3 pathway 30 (Fig. 4b,c ). Bay 11-7082 bound to GSDMD according to MST, but was less active at inhibiting liposome leakage than disulfiram (IC 50 6.81 ± 0.10 µM vs 0.30 ± 0.01 µM) (Extended Data Fig. 6a , b and Fig. 1e ). Bay 11-7082 inhibited caspase-1 similarly to disulfiram, but was about 3 times less active against caspase-11 (Extended Data Fig. 4a-d , Extended Data Fig. 6a-d) . Surprisingly, like disulfiram, Bay 11-7082 functions by inactivating reactive Cys residues 31,32 , and Cys191 in GSDMD was covalently modified by f) . However, Bay 11-7082 inhibition of liposome leakage was only reduced 2-fold by substituting C191A GSDMD for WT GSDMD in the liposome leakage assay (Extended Data Fig.   6a ). Indeed, much of Bay 11-7082 inhibition of liposome leakage could be attributed to caspase-11 inhibition, since Bay 11-7082 was substantially less able to inhibit leakage caused by GSDMD-3C plus 3C protease than by GSDMD plus caspase-11 and its activity against mouse GSDMA3-3C, which lacks a comparable reactive cysteine, plus 3C protease was similar to its activity against GSDMD-3C (Extended Data Fig. 6g ,h).
Bay 11-7082 inhibited pyroptosis triggered by both the canonical and non-canonical inflammasomes in THP-1 cells, but was more active in nigericin-treated than LPS-transfected cells ( Fig. 4c, d ). Bay 11-7082 was more effective at inhibiting canonical inflammasome-dependent pyroptosis than disulfiram in the absence of copper, and the two drugs together had an additive protective effect, although were cytotoxic at the highest concentration tested (Fig. 4c ). However, Bay 11-7082 was less active than disulfiram at inhibiting pyroptosis induced by non-canonical inflammasome activation ( Fig. 4d ).
Because both disulfiram and Bay 11-7082 non-specifically modify reactive Cys, we next analysed their effects on the steps leading to pyroptosis and inflammatory caspase activation.
Some of the genes that participate in the canonical inflammasome pathway are not expressed in unstimulated cells and their expression needs to be induced, often by binding to cell surface sensors of pathogen and danger-associated molecular patterns, such as Toll-like receptors (TLR), in a process called priming. Bay 11-7082 is known to inhibit NF-κB activation, a key transcription factor in priming. We first looked at the effect of disulfiram and Bay 11-7082 on priming ( Fig. 4e ). NF-κB activation was assessed by examining IκBα phosphorylation and degradation and RelA (p65) phosphorylation. Induction of pro-IL-1β was assessed by immunoblot for pro-IL1β protein. In the absence of disulfiram or Bay 11-7082, phosphorylation of p65 was first detected 30 min after adding LPS and persisted for 4 hrs, phosphorylation and reduced IκBα were detected 1 hr after adding LPS, and increased pro-IL-1β was detected 4 hrs after adding LPS. Both drugs, added at 30 µM concentrations, inhibited NF-κB activation, but Bay 11-7082 had a stronger effect; both blocked pro-IL-1β induction. Thus, disulfiram and Bay 11-7082 both inhibit priming.
Nigericin activates the assembly of the NLRP3 canonical inflammasome using an adaptor called apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), which can be visualized in immunofluorescent microscopy as specks. When LPS-primed THP-1 cells were treated with nigericin in the absence of inhibitors, ASC specks were detected in 30% of cells ( Fig. 4f ). As expected, speck formation was not inhibited by z-VAD-fmk, since caspase activation occurs downstream of inflammasome assembly. However, both drugs, added after priming but one hour before nigericin, inhibited ASC speck formation, but not completely, and Bay 11-7082 was more potent than disulfiram when used at the same concentration. 1 µM disulfiram was completely inactive at blocking pyroptosis triggered by nigericin or transfected LPS ( Fig. 1i,j ), but the same concentration of disulfiram in combination with copper gluconate blocked pyroptosis completely and also reduced ASC puncta ( Fig. 4g ).
Canonical inflammasome activation activates caspase-1, which cleaves pro-IL-1β and GSDMD, which forms pores needed to release processed IL-1β. To assess which steps in NLRP3-mediated inflammation were inhibited post ASC speck formation, LPS-primed THP-1 cells were treated with vehicle or 30 µM z-VAD-fmk, disulfiram or Bay 11-7082 1 hr before adding nigericin, and cleavage and activation of caspase-1, GSDMD, and pro-IL-1β were analysed by immunoblot of whole cell lysates 30 min later ( Fig. 4h ). Secretion of processed IL-1β was also assessed by immunoblot of culture supernatants. Caspase-1, GSDMD and pro-IL-1β cleavage to their active forms was clearly detected in the absence of inhibitors, but was dramatically reduced in cells treated by any of the 3 inhibitors; moreover, processed IL-1β was only detected in the culture supernatants in the absence of any inhibitor. When the same experiment was repeated by treating cells with only 1 µM disulfiram in PBS or copper gluconate, disulfiram complexed with copper completely blocked caspase-1, GSDMD, and pro-IL-1β processing and IL-1β secretion, but disulfiram without copper had no effect ( Fig. 4i ). Because immunoblots are not quantitative, we also assessed caspase-1 activity 30 min after adding nigericin using a fluorescent substrate in intact cells. While caspase-1 activity was completely inhibited by z-VAD-fmk, it was only partially reduced by either disulfiram and Bay 11-7082, again more strongly by ). Next we assessed the effect of z-VAD-fmk, disulfiram and Bay 11-7082 on LPS + nigericin-induced GSDMD pore formation by immunofluorescence microscopy using a monoclonal antibody we generated that recognizes both uncleaved GSDMD and its pore form ( Fig. 4k , Extended Data Fig. 7 ). In the absence of any inhibitor, the GSDMD antibody stained both the cytosol and the plasma membrane of LPS plus nigericin treated cells, which formed characteristic pyroptotic bubbles 10 . All 3 inhibitors completely blocked GSDMD membrane staining and the appearance of pyroptotic bubbles. Thus, disulfiram and Bay 11-7082 inhibit multiple steps leading to canonical inflammasome-induced pyroptosis and inflammatory cytokine release, including priming, inflammasome assembly, inflammatory caspase activation, pro-inflammatory cytokine processing and GSDMD pore formation.
Our identification of Cys191-modifying compounds that inhibit pore formation suggests that Cys191 is also likely modified in cells by endogenous agents, which may regulate pore formation in a redox-sensitive manner. Cysteine-reactive drugs are notoriously non-specific as to their targets. Indeed, disulfiram is used to treat chronic alcohol addiction, where it inhibits acetaldehyde dehydrogenase 12 , and is also known to inhibit multiple protein phosphatases and caspases 29, 33 . Nonetheless, disulfiram is a very safe drug even at high concentrations and has a very long half-life in tissues. We speculate that the promiscuity of disulfiram allows it to react preferentially with different targets under different conditions, e.g. with acetaldehyde dehydrogenase in alcohol addiction, or with inflammasome components, including GSDMD, during inflammation. Perhaps its lack of toxicity may be because of incomplete inhibition of individual targets that tune down a response without causing side effects. In inflammation its effectiveness may be amplified by simultaneously disrupting multiple inflammatory steps. Indeed, in our experiments, inhibition of upstream steps in inflammation, such as ASC puncta formation, tended to be partial, while inhibition of the ultimate cellular events, pyroptosis and inflammatory cytokine secretion, were more dramatic.
Inflammation appears to be especially sensitive to Cys-modifying drugs. Of note, many of the compounds that have been previously identified to inhibit other steps in priming and activating inflammasomes work by covalently binding to reactive Cys residues in inflammation pathway molecules, including the inflammatory caspase inhibitors, the diarylsulfonylureas that inhibit inflammatory cytokine release, MCC950 and 3,4-methylenedioxy-β-nitrostyrene that inactivate NLRP3, and myochrysine and related compounds that inhibit IKKβ 15 . The repeated identification of cysteine-modifying drugs as inhibitors of inflammation suggests that many inflammatory pathway molecules have reactive Cys residues, which are highly sensitive to oxidation or modification, such as Cys191 of human GSDMD that we identified here. These results in their ensemble raise the possibility that inflammation pathways are regulated by the oxidative state of a cell, namely by the generation of reactive oxygen species, and by cellular levels of antioxidants like glutathione and thioredoxin. In fact, oxidized endogenous lipids are known to regulate the non-canonical inflammasome [19] [20] [21] . A number of papers have implicated oxidation in the most studied inflammatory pathway, mediated by the NLRP3 inflammasome [16] [17] [18] 22 . However, the role of oxidation in inflammasome activation is controversial, suggesting that the overall role of oxidants and antioxidants may be a complex summation of positive and negative feedback effects that may vary in different cell types or with different inflammatory instigators. One Skrott, Z., Mistrik, M., Andersen, K. K., Friis, S., Majera, D., Gursky, J., Ozdian, T., Bartkova, J., Turi, Z., Moudry, P., Kraus, M., Michalova, M., Vaclavkova, J., Dzubak, P., Vrobel, I., Pouckova, P., Sedlacek, J., Miklovicova, A., Kutt, A., Li, J., Mattova, J., Driessen, C., Dou, Q. P., Olsen, J., Hajduch, M., Cvek, B., Deshaies, R. J. & Bartek, J.
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature 552, 194-199 (2017) . The monoclonal antibody against GSDMD was generated in house by immunizing 6
week-old BALB/c mice with recombinant human GSDMD and boosting with recombinant human GSDMD-NT according to standard protocols. Serum samples were collected to assess titers of reactive antibodies and spleen cells were fused with SP2/0 myeloma cells. Hybridomas were selected and supernatants from the resulting clones were screened by enzyme linked immunosorbent assay (ELISA), immunoblot and immunofluorescence microscopy. Tubulin antibody was from Sigma-Aldrich. Phospho-IκBα antibody, IκBα antibody, Phospho-NF-κB p65 antibody, and cleaved human caspase-1 (Asp297) antibody were from Cell Signaling Technology. ASC antibody (AL177) and mouse caspase-1 p20 antibody were from AdipoGen.
Human and mouse IL-1β antibodies were from R&D Systems. Mass spectrometry and sample preparation. Gel bands were cut into 1 mm size pieces and placed into separate 1.5 mL polypropylene tubes. 100 µl of 50% acetonitrile in 50 mM ammonium bicarbonate buffer were added to each tube and the samples were then incubated at room temperature for 20 min. This step was repeated if necessary to destain gel. Then, the gel slice was incubated with 55 mM iodoacetamide (in 50 mM ammonium bicarbonate) for 45 min in the dark at room temperature, before the gel was washed sequentially with 50 mM ammonium bicarbonate, water and acetonitrile. Samples were then dried in a Speedvac for 20 min. Trypsin (Promega Corp.) (10 ng/µL in 25 mM ammonium bicarbonate, pH 8.0) was added to each sample tube to just cover the gel, and samples were then incubated at 37 °C for 6 hrs or overnight.
After digestion, samples were acidified with 0.1% formic acid (FA) and 3 µl of tryptic peptide with a complete protease inhibitor cocktail (Roche) and a PhosSTOP phosphatase inhibitor cocktail (Roche). Samples were subjected to SDS-PAGE and the resolved proteins were then transferred to a PVDF membrane (Millipore). Immunoblots were probed with indicated antibodies and visualized using a SuperSignal West Pico chemiluminescence ECL kit (Pierce) .
Caspase-1 activity assay in cells.
To measure caspase-1 activation, THP-1 cells were seeded into 96-well plates and differentiated with PMA. After the indicated treatments, cells were incubated with a fluorescent active caspase-1 substrate FAM-YVAD-FMK (Immunochemistry Technologies). Samples were read on a BioTek Synergy 2 plate reader.
Measurement of cytokines.
Concentrations of IL-1β in culture supernatants or mouse serum were measured by ELISA kit (R&D Systems) according to the manufacturer's instructions.
Immunostaining and confocal microscopy. Cells grown on coverslips were fixed for 15 min with 4% paraformaldehyde in PBS, permeabilized for 5 min in 0.1% Triton X-100 in PBS and blocked using 5% BSA for 1 hr. Then, cells were stained with the indicated primary antibodies followed by incubation with fluorescent-conjugated secondary antibodies (Jackson ImmunoResearch). Nuclei were counterstained with DAPI (4,6-diamidino-2-phenylindole) (Sigma-Aldrich). Slides were mounted using Aqua-Poly/Mount (Dako). Images were captured using a laser scanning confocal microscope (Olympus Fluoview FV1000 Confocal System) with a 63× water immersion objective and Olympus Fluoview software (Olympus). All confocal images are representative of three independent experiments.
Statistics. Student's t-test was used for the statistical analysis of two independent treatments.
Mouse survival curves and statistics were analyzed using the Mantel-Cox Log-rank test. 
